This breakthrough, which is a first in the Triad, offers a new option for patients with severe tricuspid regurgitation, a ...

CHICAGO -- Champions of tricuspid transcatheter edge-to-edge repair (TEER) were buoyed by 2-year results of the TRILUMINATE trial marking the first report of reduced heart failure (HF) hospitalization ...

The FDA approved the Evoque tricuspid valve replacement system as the first transcatheter treatment for tricuspid regurgitation (TR), Edwards Lifesciences announced. Evoque gained an indication for ...

Surgeons at Gleneagles Hospitals successfully performed Transcatheter Tricuspid Valve Edge-to-Edge Repair on a 75-year-old ...

Patients already had high NT-proBNP levels at baseline, though, raising questions about the quality of GDMT, Nancy Sweitzer ...

PARIS, France—Percutaneous edge-to-edge repair with a clip device appears to offer some hope for patients with tricuspid regurgitation, according to new results from the TRILUMINATE study. At 30 days, ...

VDyne Inc. ("VDyne"), a privately held medical device company developing a transcatheter tricuspid valve replacement (TTVR) system to treat tricuspid regurgitation, today announced the appointment of ...

Tricuspid valve repair at the time of mitral-valve surgery reduces tricuspid regurgitation progression but at the cost of more than a 5-fold increase in permanent pacemakers, a new Cardiothoracic ...

The investigational transfemoral EVOQUE tricuspid valve replacement system (Edwards Lifesciences) significantly reduced severity of tricuspid regurgitation and improved quality of life at 30 days in ...

Henry Ford Health cardiologists are the first to offer new Tri-Clip procedure to patients for whom open-heart surgery isn’t an option A breakthrough in treating tricuspid regurgitation, or TR, is ...

At 2 years, more than 90% of patients were alive and free from mitral valve reoperation or severe recurrent MR. The incidence ...